Alternative use of bisphosphonate therapy for rheumatic disease.

Abstract:

:Bisphosphonates are widely use for pathologies such as osteoporosis, Paget's disease or bone metastasis. However, their potent antiresorptive properties open new therapeutic opportunities for other conditions associated with an increased focal or systemic bone remodelling. Moreover, apart from their antiresorptive activity, bisphosphonates could also have others properties through a specific analgesic or anti-inflammatory effect. Thus, rheumatic diseases like rheumatoid arthritis, spondylarthritis or SAPHO syndrome (acronym for synovitis, acne, pustulosis, hyperostosis and osteitis) that are associated with systemic and sometimes focal bone loss could be good candidates for bisphosphonate therapy. Other non-inflammatory rheumatic diseases like bone osteonecrosis, algodystrophy, fibrous dysplasia or neuropathic osteoarthropathy are also associated with pain and an increase of focal bone remodelling. Several studies have shown that bisphosphonate could have promising therapeutic potential in these inflammatory or non-inflammatory diseases where therapeutic options are usually few. This review will focus on the new potential alternative indications for bisphosphonate in rheumatic diseases.

journal_name

Curr Pharm Des

authors

Le Goff B,Berthelot JM,Maugars Y,Romas E

doi

10.2174/138161210793563626

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

3045-52

issue

27

eissn

1381-6128

issn

1873-4286

pii

BSP/CPD/E-Pub/000206

journal_volume

16

pub_type

杂志文章,评审
  • Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

    abstract::P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP re...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212803251934

    authors: Laine M,Camoin-Jau L,Bessereau J,Sébastien A,Paganelli F,Bonello L

    更新日期:2012-01-01 00:00:00

  • Cardio-protective effects of sodium-glucose co-transporter 2 inhibitors: focus on heart failure.

    abstract:BACKGROUND:Type 2 diabetes mellitus (DM) is associated with a considerable risk of cardiovascular and renal disease, including heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated unprecedented cardiorenal protective effects in large scale clinical trials of patients with or without diabet...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666201103122813

    authors: Karangelis D,Mazer CD,Stakos D,Tzifa A,Loggos S,Verma S,Mitropoulos F

    更新日期:2020-11-03 00:00:00

  • Role of dendritic cell-derived cytokines in immune regulation.

    abstract::Over the last several years, it has become increasingly clear that dendritic cells (DC) are not only critical for the initiation of T cell immunity, but these cells also determine the course of the subsequent immune response (i.e. tolerance vs. immunity, Th1 vs. Th2). However, the mechanisms by which DC can influence ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612013397627

    authors: Wan Y,Bramson J

    更新日期:2001-07-01 00:00:00

  • Effects of an Integrative Mind-body-medicine Group Program for Breast Cancer Patients during Chemotherapy: An Observational Study.

    abstract:BACKGROUND:Breast cancer is one of the leading cancers in women in the Western world. Cancer treatment, especially chemotherapy, is often associated with physical and psychosocial side effects. OBJECTIVE:To improve the quality of life and manage side effects, a new integrative mind-body-medicine group concept for brea...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666201211111122

    authors: Haller H,Choi KE,Lange S,Kümmel S,Paul A,Cramer H,Dobos G,Voiss P

    更新日期:2020-12-10 00:00:00

  • Role of the peroxynitrite-poly (ADP-ribose) polymerase pathway in the pathogenesis of liver injury.

    abstract::Oxidative and nitrosative stress triggers DNA strand breakage, which then activates the nuclear enzyme poly(ADP-ribose) polymerase (PARP). One of the key triggers of DNA single strand breakage in pathophysiological conditions is peroxynitrite, a reactive species produced from the reaction of nitric oxide and superoxid...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206777947579

    authors: Gero D,Szabó C

    更新日期:2006-01-01 00:00:00

  • Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.

    abstract::Despite the significant progresses made in antiretroviral therapy, current drugs still cannot cure or prevent HIV infection. And all drugs continue to select for drug-resistant HIV strains. Consequently, new antiretroviral drugs are constantly being developed. To ensure safety, these drugs are usually designed to inhi...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612043382422

    authors: Provencher VM,Coccaro E,Lacasse JJ,Schang LM

    更新日期:2004-01-01 00:00:00

  • Comparative genomics for the investigation of autoimmune diseases.

    abstract::The complete DNA sequence of the human genome and of several related mammals are now available, due to the investments of enormous resources and advances in sequencing technology. Novel technologies have been developed to compare multiple genomes with each other, thus specifying regions of sequence similarity among ma...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206778559795

    authors: Möller S,Zettl UK,Serrano-Fernández P,Goertsches R

    更新日期:2006-01-01 00:00:00

  • Early life and oxidative stress in psychiatric disorders: what can we learn from animal models?

    abstract::Schizophrenia is a complex pathology characterized by the occurrence of a variety of symptoms classified as positive, negative and cognitive. Although the exact etiopathogenesis of this disorder has not been unraveled yet, many theories have been endorsed during the last years. Among these, the neurochemical theories ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150105122422

    authors: Mhillaj E,Morgese MG,Trabace L

    更新日期:2015-01-01 00:00:00

  • Dietary Supplements: Foods, Medicines, or Both? A Controversial Designation with Unspecific Legislation.

    abstract:BACKGROUND:Dietary supplements have been widely used among the United States of America (USA) and the European Union (EU) population not only as a form of nutrition but also for medicinal purposes. Still, the legislation regulating these supplements remains unclear due to the fact that they can be considered as foodstu...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170117122801

    authors: Pereira C,Barros L,Ferreira ICFR

    更新日期:2017-01-01 00:00:00

  • Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases.

    abstract::Insight is provided herein into the novel mechanisms of cardiometabolic risk. Previous reports, including the epidemiological work of the Turkish Adult Risk Factor study, indicated that proinflammatory state and oxidative stress are crucial for evaluating cardiometabolic risk. Autoimmune pathways in the course of oxid...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161282004140213145551

    authors: Onat A,Can G

    更新日期:2014-01-01 00:00:00

  • An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.

    abstract::Adenosine A(2A)-dopamine D(2) receptor interactions play a very important role in striatal function. A(2A)-D(2) receptor interactions provide an example of the capabilities of information processing by just two different G protein-coupled receptors. Thus, there is evidence for the coexistence of two reciprocal antagon...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208784480108

    authors: Ferré S,Quiroz C,Woods AS,Cunha R,Popoli P,Ciruela F,Lluis C,Franco R,Azdad K,Schiffmann SN

    更新日期:2008-01-01 00:00:00

  • Drug carriers in pharmaceutical design: promises and progress.

    abstract::Ever since pure molecular entities have been adapted as drug, varied manifestations other than elimination of infections are frequently been acknowledged as side effects. Contemporary drug research focuses on these issues besides developing new molecules for the restoration of unnatural functional deviations in variou...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207780249119

    authors: Dutta RC

    更新日期:2007-01-01 00:00:00

  • Modified polysaccharides as versatile materials in controlled delivery of antidegenerative agents.

    abstract::The mechanisms and factors causing or influencing degenerative diseases require tailor-made solutions. Natural polysaccharides are among the most versatile building units of the novel drug delivery systems. Their properties can be easily tailored to specific needs because they depend not only on the first-order struct...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212800492831

    authors: Karewicz A,Bielska D,Nowakowska M

    更新日期:2012-01-01 00:00:00

  • Optimization of cardiac metabolism in heart failure.

    abstract::The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utilization of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides the highest energy yield per molecule of substrate metab...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211798357773

    authors: Nagoshi T,Yoshimura M,Rosano GM,Lopaschuk GD,Mochizuki S

    更新日期:2011-12-01 00:00:00

  • Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.

    abstract::Many of the most debilitating symptoms for psychiatric disorders such as schizophrenia remain poorly treated. As such, the development of novel treatments is urgently needed. Unfortunately, the costs associated with high failure rates for investigational compounds as they enter clinical trials has led to pharmaceutica...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160127113912

    authors: Wylie KP,Smucny J,Legget KT,Tregellas JR

    更新日期:2016-01-01 00:00:00

  • Opiophobia in Cancer Biology- Justified? - The Role of Perioperative Use of Opioids in Cancer Recurrence.

    abstract::Opioids remain the standard of care in the provision of analgesia in the patient undergoing cancer surgery preoperatively. The effects of opioids on tumor growth and metastasis have been discussed for many years. In recent years their use as part of the perioperative pain management bundle in the patients undergoing c...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666190703163329

    authors: Sekandarzad MW,Doornebal C,Hollmann MW

    更新日期:2019-01-01 00:00:00

  • Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.

    abstract::Reducing sugars can react non-enzymatically with amino groups of proteins and lipids to form irreversibly cross-linked macroprotein derivatives called as advanced glycation end products (AGEs). Cross-linking modification of extracellular matrix proteins by AGEs deteriorate their tertiary structural integrity and funct...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666161021155502

    authors: Yamagishi SI,Matsui T,Ishibashi Y,Isami F,Abe Y,Sakaguchi T,Higashimoto Y

    更新日期:2017-01-01 00:00:00

  • Left ventricular non-compaction: from recognition to treatment.

    abstract::We have gained considerable insight and understanding about the etiology, embryogenesis of the myocardium, genetic background, diagnosis and outcome of left ventricular non-compaction (LVNC) over the last 2 decades. LVNC has a distinct morphological appearance with a thickened, two-layered myocardium consisting of an ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161282104141204143212

    authors: Ganame J

    更新日期:2015-01-01 00:00:00

  • Polysaccharide Colloids as Smart Vehicles in Cancer Therapy.

    abstract::Cancer disease is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and around 8 million cancer-related deaths yearly. Estimates expect to increase these figures over the next few years. Therefore, it is very important to develop more effective and targeted therapi...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150820100812

    authors: Caro C,Pozo D

    更新日期:2015-01-01 00:00:00

  • Anti-VEGF Molecules for the Management of Diabetic Macular Edema.

    abstract::Diabetic macular edema (DME) represents the most common cause of vision loss in patients affected by diabetes mellitus. Although the pathophysiology of DME is not wholly understood, vascular endothelial growth factor (VEGF) has been identified as a key contributor to the development of DME. In addition, latest informa...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150909095756

    authors: Bandello F,Cicinelli MV,Parodi MB

    更新日期:2015-01-01 00:00:00

  • Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism.

    abstract:BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,meta分析

    doi:10.2174/138161205774580534

    authors: Iorio A,Guercini F,Ferrante F,Nenci GG

    更新日期:2005-01-01 00:00:00

  • Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.

    abstract::Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially co...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209789105054

    authors: Florentin M,Elisaf MS,Mikhailidis DP,Liberopoulos EN

    更新日期:2009-01-01 00:00:00

  • Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection.

    abstract::Humans have always lived with tubercle bacilli. Host susceptibility both inherited and acquired determines whether an individual infected with Mycobacterium tuberculosis will eventually fall ill and develop tuberculosis (TB). After infection with M. tuberculosis, a latent TB infection may ensue reflected by immune r...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797470228

    authors: van Altena R,Duggirala S,Gröschel MI,van der Werf TS

    更新日期:2011-01-01 00:00:00

  • The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer's Disease.

    abstract::Drug development for neurodegenerative diseases such as Alzheimer's disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developi...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150130120358

    authors: Gomes B,Loureiro JA,Coelho MA,Pereira Mdo C

    更新日期:2015-01-01 00:00:00

  • Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate.

    abstract:AIMS:To compare the efficacy of pemafibrate (PF) and fenofibrate (FF) in treating dyslipidemia. METHODS:A comprehensive search was performed on the public database to identify relevant randomized controlled trials (RCTs), which compared the effects of PF and FF treatment in lipid parameters among patients with dyslipi...

    journal_title:Current pharmaceutical design

    pub_type: meta分析

    doi:10.2174/1381612825666191126102943

    authors: Wang H,Li H,Zhou Y,Liu J,Wang F,Zhao Q

    更新日期:2019-01-01 00:00:00

  • The role of microRNAs in the pathogenesis and treatment of hematopoietic malignancies.

    abstract::microRNAs (miRNAs) comprise a recently discovered class of non-coding RNAs with regulatory functions in post-transcriptional gene expression control. Many miRNAs are located in genomic regions that are frequently deleted in cancer, or are subject to epigenetic and transcriptional deregulation in cancer cells. The miRN...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161213804805649

    authors: Schmid CA,Craig VJ,Müller A,Flori M

    更新日期:2013-01-01 00:00:00

  • Pharmacophore identification and quantitative bioactivity prediction using the electron-conformational method.

    abstract::A review of the Electron-Conformational (EC) method of pharmacophore (Pha) identification and quantitative bioactivity prediction in drug design and toxicology is presented, which includes the latest advances and improvements of the method as a whole and details of its realization with illustration of results. In the ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033454586

    authors: Bersuker IB

    更新日期:2003-01-01 00:00:00

  • The Insular Cortex and Takotsubo Cardiomyopathy.

    abstract::Transient left ventricular dysfunction in patients under emotional stress, also known as Takotsubo cardiomyopathy, has been recognized as a distinct clinical entity. Recent studies have supported the concept notion that the cardiovascular system is regulated by cortical modulation. A network consisting of the insular ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666161006123530

    authors: Nagai M,Dote K,Kato M,Sasaki S,Oda N,Kagawa E,Nakano Y,Yamane A,Higashihara T,Miyauchi S,Tsuchiya A,Harada W,Kario K

    更新日期:2017-01-01 00:00:00

  • Quantitative electroencephalogram (EEG) in insomnia: a new window on pathophysiological mechanisms.

    abstract::In the last two decades quantitative electroencephalogram (EEG) analysis has been widely used to investigate the neurophysiological characteristics of insomnia. These studies provided evidence in support of the hypothesis that primary insomnia is associated with hyperarousal of central nervous system and altered sleep...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208786549326

    authors: Marzano C,Ferrara M,Sforza E,De Gennaro L

    更新日期:2008-01-01 00:00:00

  • Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs.

    abstract::Prostacyclin (PGI(2)) is one of the major vascular protectors against thrombosis and vasoconstriction, caused by thromboxane A(2). Understanding the molecular mechanisms of PGI(2) biosynthesis and signaling is crucial to the development of therapeutic approaches to regulate PGI(2) functions. This review provides infor...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206776055994

    authors: Ruan KH,Dogné JM

    更新日期:2006-01-01 00:00:00